IONIQ Sciences recognized as “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021″
December 16, 2021
IONIQ Sciences, Inc. announced it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021” by Global 100. One of the critical innovations we believe that separates our IONIQ ProLung Test from other potential tests is in precisely what we are measuring. Using a novel application of bioimpedance technology, we believe we’re measuring the body’s systemic response to cancer. This enables earlier detection, and quite possibly detection of a wide array of cancers not tied to specific tumor types or sizes. Our ability to detect smaller 4-8mm pulmonary nodules in early cancer stages with greater accuracy than existing diagnostics is what earned us a ‘Breakthrough Device’ designation from the FDA.
Read the Original Announcement here »
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
